Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New diabetes drug safety check in pakistan: empagliflozin under Real-World watch

NCT ID NCT05164263

First seen Jan 31, 2026 · Last updated Apr 30, 2026 · Updated 7 times

Summary

This study looks at how safe and effective empagliflozin (taken with or without metformin) is for adults with type 2 diabetes in Pakistan. About 156 people aged 18 to 65 with poorly controlled diabetes will be followed for 6 months. Researchers will track side effects like low blood sugar, infections, and stomach issues, and measure changes in blood sugar and weight.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SAFETY ISSUES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Agha Khan univeristy hospital

    RECRUITING

    Nairobi, Kenya, Kenya

    Contact

  • Kabul University of Medical Sciences(KUMS)

    COMPLETED

    Kabul, Afghanistan, Afghanistan

  • Lagos University Teaching Hospital

    RECRUITING

    Lagos, Nigeria, Nigeria

    Contact

    Contact

    Contact

  • NHK

    COMPLETED

    Kandy, Kandy, Sri Lanka

  • National hospital Sri Lanka

    COMPLETED

    Colombo, Colombo, Sri Lanka

  • Umar Diabetes Foundation

    COMPLETED

    Islamabad, Pakistan

Conditions

Explore the condition pages connected to this study.